Lantheus Medical Imaging's PET radiotracer Pylarify (F-18 piflufolastat) has been included in the National Comprehensive Cancer Network (NCCN) guidelines for imaging prostate cancer.
Pylarify is a radiopharmaceutical developed for PET imaging of prostate specific membrane antigen (PSMA)-positive lesions in men with prostate cancer who are candidates for surgery or who are suspected of recurrence based on elevated serum prostate-specific antigen (PSA) levels.
Pylarify is labeled with F-18 and homes in on PSMA, a protein that is overexpressed on the surface of more than 90% of both primary and metastatic prostate cancer cells. PET imaging can detect accumulations of the agent at sites of prostate cancer, making Pylarify useful for detecting metastasis from primary cancer or recurrence of disease in men who have already been treated.
Lantheus received approval from the U.S. Food and Drug Administration (FDA) for Pylarify in May.
The NCCN is a not-for-profit alliance of 31 cancer centers devoted to patient care, research, and education. The organization's guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors, Lantheus stated in a press release.
